Table 3.
Diagnosis accuracy assessment of IL-12p70, IL-17, HDL-C and their combination in predicting severe CAD.
| IL-12p70 | IL-17 | HDL-C | Model A | Model B | |
|---|---|---|---|---|---|
| Sensitivity (%) | 45.3 (39.0–51.8) | 44.1 (37.8–50.5) | 56.0 (49.5–62.3) | 68.3(62.0–74.0) | 64.2 (57.8–70.2) |
| Specificity (%) | 77.8 (72.1–82.6) | 79.0 (73.4–83.7) | 73.8 (67.9–79.0) | 63.7 (57.4–69.5) | 73.8 (67.9–79.0) |
| Positive predictive value (%) | 66.1 (58.3–73.1) | 66.7 (58.8–73.8) | 67.0 (60.0–73.3) | 64.1 (57.9–69.9) | 70.0 (63.4–75.8) |
| Negative predictive value (%) | 59.9 (54.4–65.1) | 59.7 (54.3–64.9) | 63.8 (58.1–69.3) | 67.9 (61.6–73.7) | 68.5 (62.6–73.8) |
| False positive (%) | 33.9 (26.9–41.7) | 33.4 (26.2–41.2) | 33.0 (26.7–40.0) | 35.9 (30.1–42.1) | 30.0 (24.2–36.6) |
| False negative (%) | 40.1 (34.9–45.6) | 40.3 (35.1–45.7) | 36.1 (30.7–41.9) | 32.1 (26.3–38.4) | 31.5 (26.2–37.4) |
| Positive likelihood ratios | 2.043 (1.564–2.668) | 2.098 (1.592–2.764) | 2.138 (1.692–2.702) | 1.880 (1.565–2.259) | 2.452 (1.956–3.075) |
| Negative likelihood ratios | 0.703 (0.626–0.789) | 0.708 (0.632–0.793) | 0.596 (0.516–0.689) | 0.498 (0.412–0.601) | 0.484 (0.409–0.575) |
Model A: the combination of IL-12p70, IL-17, and HDL-C.
Model B: the combination of combined IL-12p70, IL-17, HDL-C, gender, and diabetes.